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Abstract: Coronary artery calcium (CAC) has been advocated as one of the strongest 
cardiovascular risk prediction markers. It performs better across a wide range of 
Framingham risk categories (6%–10% and 10%–20% 10-year risk categories) and also 
helps in reclassifying the risk of these subjects into either higher or lower risk categories 
based on CAC scores. It also performs better among population subgroups where 
Framingham risk score does not perform well, especially young subjects, women, family 
history of premature coronary artery disease and ethnic differences in coronary risk.  
The absence of CAC is also associated with excellent prognosis, with 10-year event rate of 
1%. Studies have also compared with other commonly used markers of cardiovascular 
disease risk such as Carotid intima-media thickness and highly sensitive C-reactive protein. 
CAC also performs better compared with carotid intima-media thickness and highly 
sensitive C-reactive protein in prediction of coronary heart disease and cardiovascular 
disease events. CAC scans are associated with relatively low radiation exposure (0.9–1.1 mSv) 
and provide information that can be used not only for risk stratification but also can be 
used to track the progression of atherosclerosis and the effects of statins. 
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1. Introduction 
Atherosclerosis coronary artery disease is among the leading cause of morbidity and mortality in the 
Western world. The shear burden of cardiovascular disease on healthcare costs is enormous, with an 
estimate of 475 billion US dollars spent in the year 2009 alone [1]. By 2030, real total direct medical 
costs of cardiovascular disease (CVD) are projected to increase to ≈ $ 918 billion [2]. In order to drive the 
cost down, emphasis is on preventive measures and earlier detection of cardiovascular disease. There 
is a number of risk factors algorithms, biomarkers and imaging studies to screen for cardiovascular 
diseases. Framingham risk scores (FRS), Reynolds risk score, highly sensitive C-reactive protein  
(hs-CRP), carotid intima media thickness (CIMT) and coronary artery calcium (CAC) are among the 
various measures that can be used for screening of cardiovascular disease among asymptomatic 
population. CAC score has emerged as one of the strongest risk prediction tools. It represents calcific 
atherosclerosis in the coronary arteries and correlates well with the overall burden of atherosclerosis in 
the coronary arteries. The current review article will compare CAC score with the remaining risk 
stratification tools. 
2. Framingham Risk Score and Coronary Artery Calcium 
Framingham risk score is the most commonly used cardiovascular risk stratification tool in the 
general population due to its ease of use. It takes into account major cardiovascular risk factors 
including age, sex, dyslipidemia, smoking and hypertension [3]. This risk scoring system predicts an 
estimate of population risk for CVD events over 10-years and categorizes individual risk for developing 
CVD to low (10-year risk of <10%), intermediate (10-year risk of 10%–20%), and high (10-year risk of 
>20%) risk. FRS is easy to calculate and provides a good overall estimate of patient risk for future 
cardiovascular problems. However, there are several limitations to the use of this classification for risk 
assessment in the general population. 
Shaw et al. [4] followed up a cohort of 10,377 asymptomatic individuals for mean duration of  
five years and compared cardiac risk factors such as family history of coronary artery disease, 
hypercholesterolemia, hypertension, smoking and diabetes mellitus with CAC score (Figure 1). CAC 
was found to be an independent predictor of mortality (p < 0.001) and it provided improved 
discrimination value compared to the cardiac risk factors alone (concordance index 0.78 vs. 0.72,  
p < 0.001) in a multivariable model for prediction of death. CAC was also superior to estimated 
Framingham risk score in outcome classification ability (Area under the ROC curve = 0.73 vs. 0.67,  
p < 0.001). 
Greenland et al. [5] evaluated predictive value of CAC across increasing levels of FRS categories 
(0%–9%, 10%–15%, 16%–20% and ≥21%). For low risk FRS categories (0%–9%), CAC >300 did not 
provide an increased risk. CAC >100 was associated with increased risk among FRS categories  
10%–15% and higher. The risk associated with FRS category 10%–15% and CAC score >300 (hazard 
ratio 17.6, p < 0.001) was comparable with the risk associated with FRS category >21% and CAC 
>300 (hazard ratio 19.1, p < 0.001). 2010 American College of Cardiology (ACC) and American Heart 
Association (AHA) guidelines [6] have incorporated CAC for cardiovascular risk assessment in 
asymptomatic adults at intermediate risk (10%–20% 10-year risk) (Class II a indication). The current 
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clinical practice guidelines [6] do not recommend the use of CAC for low risk population risk 
assessment. Okwuosa et al. [7] evaluated the prevalence of CAC in low risk FRS categories and the 
number needed to screen to detect one individual with CAC score >300. There were 1.7% and 4.4% of 
the population found to have CAC score ≥300 within FRS categories of 0%–2.5% and 2.6%–5.0%, 
respectively. The respective number needed to screen were 59.7 and 22.7. The number needed to screen to 
detect persons with CAC score ≥300 decreased with increasing FRS categories; with only 4.2 and  
3.3 individuals needed to be screened with FRS of 15.1%–20% and >20%. Okwuosa et al. [8] 
evaluated role of novel markers for CAC score progression among patients within low risk FRS 
category (<10%). They looked at the following variables: LDL particle number (LDLpn), urine 
albumin, CRP using a high-sensitivity assay, D-dimer, factor VIIIc, total homocysteine (tHcy), 
fibrinogen, cystatin C, soluble intercellular adhesion molecule-1 (sICAM-1) and carotid intima media 
thickness (CIMT). The study showed significant association of most of these risk factors with CAC 
progression in univariate and age adjusted models. This statistical significance was lost after 
adjustment for traditional cardiovascular risk factors. The study also evaluated predictive value of 
various combinations of novel markers with CAC progression compared with a base model composed 
of traditional risk factors. These combination models showed little or no improvement over the base 
model in discrimination and informativeness. Taylor et al. [9] performed a study evaluating the 
predictive value of CAC in 2000 healthy young men and women aged 40–50 years of age. A total of 
nine coronary events occurred, with four in men with 10-year FRS risk <6% and five men with 10-year 
FRS risk of 6%–10%. None of the events occurred in men with 10-year FRS risk above 10%. Seven 
out of nine men had CAC among those who suffered coronary heart disease (CHD) events. This study 
showed that the presence of any CAC was associated with an 11.8-fold increased risk of acute CHD  
(p = 0.002) after controlling for the FRS. 2010 ACC/AHA guidelines [6] suggest use of CAC for 
cardiovascular risk assessment of individuals with 10-year FRS risk of 6%–10% (Class II b 
indication). The current clinical practice guidelines do not recommend the use of CAC for low risk 
individuals (10-year FRS risk <6%) for cardiovascular risk assessment (Class III indication). The study 
performed by Greenland et al. [5] did not show any benefit of cardiovascular risk assessment with  
CAC score in the 10-year FRS category of less than 10%. The mean age of population at the time  
of computed tomography (CT) scan in this study was 65.7 years. The population groups in both  
Taylor et al. [9] (mean age 43 years) and Okwuosa et al. [7] were younger (mean age: 60.9 years, 53% 
women). It is already known that the FRS performs poorly in younger patients and women [10–12].  
In a multi-ethnic study of atherosclerosis, 90% of the women were classified as low risk based on FRS 
risk classification [13]. There were 32% of low risk women who were found to have CAC score of 
more than 0 (four percent had CAC score ≥300). In these women, CAC score of >300 were highly 
predictive of future CHD and CVD events (6.7% and 8.6% absolute CHD and CVD risk, respectively) 
over a 3.75 year period. Ninety-five percent of the US women younger than 70 are found to be at  
low risk for coronary heart disease according to the data from Third National Health and Nutrition 
Examination Survey (NHANES III) [10] and, thereby, do not qualify for more aggressive medical 
management for standard risk factors according to the National Cholesterol Education Program Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III) (NCEP/ATP III) [14]. These persons otherwise may be classified as low-risk, and may not 
benefit from preventive treatments that can otherwise be offered to them based on CAC scores. 
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Elias-Smale et al. [15] evaluated the effect of CAC in risk assessment of elderly population (2028 
subjects, age 69.6 ± 6.2 years and showed that CAC was able to reclassify 52% of men and women in 
intermediate risk category. 
 
Figure 1. Predictive value of coronary artery calcium [4]. 
Family history of premature coronary artery disease represents a unique situation. The persons may 
suffer from cardiovascular events at an earlier age. The usual risk stratification tools such as FRS may 
perform poorly in these persons. Reynolds risk score includes parental family history of premature 
CAD and high-sensitivity C-reactive protein (hs-CRP) to traditional risk factors. CAC use has been 
assessed in this situation as well [16–18]. Nasir et al. [16] showed that the age-, gender- and  
race-adjusted prevalence of CAC >0 was significantly higher with presence of any family history of 
premature CHD than those with no family history of premature CHD among individuals classified as 
low risk (35% vs. 23%, p < 0.0001) and among those at intermediate risk (70% vs. 60%, p = 0.01). 
Similar results were seen with CAC ≥75th percentile among individuals at low risk (24% vs. 14%,  
p = 0.0003) and intermediate-risk (34% vs. 20%, p < 0.001) respectively. A post hoc analysis from  
St. Francis Heart study [17] revealed benefit of statin treatment in individuals with a family history of 
premature CAD and CAC above 80th percentile. 
CAC has been shown to perform better across a wide range of FRS categories (6%–10% 10-year 
risk and 10%–20% 10-year risk). FRS is a population-based risk of 10-year event rates; however, 
individual persons may not be at the same level of risk in each category as determined by FRS. The 
individual risk can be further stratified with the use of various markers like hs-CRP and CAC.  
Polonski et al. [19] showed that addition of CAC to traditional risk factors improves risk prediction 
significantly compared to traditional risk factors alone. Traditional risk factors were able to classify 
69% of the cohort into the highest or lowest risk categories, whereas addition of CAC to this model 
increased it to 77%. CAC along with traditional risk factors was able to reclassify 23% of those who 
had cardiac events into high risk and 13% without cardiac events into low risk. 
Coronary atherosclerosis burden differs between different ethnic groups [20]. Framingham risk  
score does not account for the ethnicities. Detrano et al. [20] performed coronary calcium scans on 
population-based sample of 6722 men and women, of whom 38.6% were white, 27.6% were black, 
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21.9% were Hispanic, and 11.9% were Chinese. They found that adjusted risk for any coronary events 
for CAC score categories 1–100, 101–300 and >300 increased by a factor of 3.61-fold, 7.73-fold and 
9.67-fold when compared with CAC score of zero (p < 0.001, respectively). The adjusted risk for any 
coronary events for ethnic groups Whites, Chinese, Black and Hispanics was 1.22-fold (p < 0.001), 
1.36-fold (p < 0.005), 1.39-fold (p < 0.001) and 1.18-fold (p < 0.001), respectively. Across four ethnic 
groups, a doubling of CAC increased the risk of major coronary event by 15%–35% and the risk of any 
coronary event by 18%–39%. The areas under the receiver-operating-characteristic curve showed 
superior predictive value of CAC compared to the standard risk factors for both major and any 
coronary events. 
The predictive value of increasing CAC score is well established. The protective value of CAC 
score zero is also very promising. A number of studies have consistently reported better outcomes 
associated with the absence of CAC (Table 1). These persons may require less intensive treatments and 
further diagnostic testing due to very low event rates in this population group. Blaha et al. [21] 
evaluated annualized all-cause mortality rates in 44,052 consecutive asymptomatic patients referred for 
CAC testing. They found that 45% had no CAC on screening and there were 104 deaths in those with 
CAC score zero. Patients with CAC score of 0 have an excellent prognosis, with a 10-year event rate of 
about 1%. 
Table 1. Predictive value of zero coronary artery calcium score. 
Author Year 
Total No. of 
Participants 
Participants with 
CAC Score 0 
Event Rate Follow up Period 
Blaha et al. [21] 2009 44,052 19,898 0.87/1000 person-years 
Mean follow-up of 
5.6 ± 2.6 years 
Arad et al. [22] 2005 4613 1504 1/1000 person-years 4.3 years 
Taylor et al. [9] 2005 2000 1263 0.6/1000 person-years 
Mean follow-up of 
3.0 ±1.4 years 
Budoff et al. [23] 2007 25,253 11,046 0.6/1000 person-years 
Mean follow-up of 
6.8 ± 3 years 
Detrano et al. [20] 2009 6722 3409 0.6/1000 person-years 3.7 years 
Shaw et al. [4] 2003 10,377 5067 1.5 events/1000 person-years 
Mean follow-up of 
5.0 years 
LaMonte et al. [24] 2005 10,746 2692 1.6 events/1000 person-years 3.5 years 
The value of CAC in cardiac disease prediction has been well established. Herman et al. [25] 
evaluated association of CAC with stroke and showed that log10 (CAC + 1) is an independent 
predictor of stroke (hazards ratio, 1.52 (95% confidence interval, 1.19–1.92); p = 0.001) in addition  
to age, systolic blood pressure and smoking in subjects at low or intermediate vascular risk.  
This association was independent of atrial fibrillation detected at baseline and follow up exams in 
prediction of stroke (fully adjusted hazard ratio, 1.31 (1.00–1.71); p = 0.049) that may be the 
underlying cause for cryptogenic strokes. O’Neal et al. [26] showed that higher CAC scores were 
associated with increased risk for atrial fibrillation (CAC = 1–100: Hazard Ratio 1.4, 95% CI 1.01–2.0;  
CAC = 101–300: HR 1.6, 95% CI 1.1–2.4; CAC > 300: HR 2.1, 95% CI 1.4–2.9) in a model adjusted 
for sociodemographics, cardiovascular risk factors, and potential confounders. 
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The recently published ACC/AHA guidelines on the assessment of cardiovascular risk [27] used  
a different risk tool to estimate 10-year and long term risk of atherosclerotic cardiovascular disease 
(ASCVD) that incorporates age, sex, race, HDL-cholesterol, total cholesterol, diabetes, systolic blood 
pressure or treatment for hypertension and smoking status. This new risk stratification tool may replace 
FRS for risk prediction. However there are currently no studies available that compare CAC with 10-year 
ASCVD risk tool. 
3. Reynolds Risk Score and Coronary Artery Calcium 
Reynolds risk score (RRS) includes traditional risk factors used in FRS and adds parental family 
history of premature CAD and high-sensitivity C-reactive protein (hs-CRP) [28]. It provides improved 
prediction of CVD events in both men and women and has been proposed as an alternative to FRS in 
risk stratification [28,29]. DeFillepis et al. [30] compared the performance of FRS and RRS in 
predicting CAC incidence and progression among 5140 individuals in MESA population. Both FRS 
and RRS were predictive of incident CAC (relative risk: 1.40 and 1.41 per 5% increase in risk, 
respectively) and CAC progression (relative risk 6.92 and 6.82 per 5% increase in risk, respectively). 
There was discordance in risk category classification (<10% and >10% per 10-year HD risk) in 13.7% 
of patients. RRS was found superior to FRS in providing additional predictive information for incidence 
and progression of CAC when discordance between the scoring systems existed. Desai et al. [31] 
evaluated whether CAC leads to reclassification of RRS risk assessment in patients without prior 
CHD. There were 72% of patients with CAC score >400 and 88% of patients with high CAC 
percentile had low or intermediate risk by RRS risk classification. CAC can potentially improve risk 
reclassification for RRS risk assessment. 
4. Carotid Intima Media Thickness and Coronary Artery Calcium 
Carotid intima-media thickness (CIMT) represents carotid atherosclerosis and is being used as  
a surrogate marker for atherosclerosis. Its utility relies on its ability to predict future adverse 
cardiovascular events [32]. Lorenz et al. [33] performed a meta-analysis of eight studies where they 
showed that the age- and sex-adjusted overall estimates of the relative risk of 1.26 (95% CI 1.21–1.30) 
for myocardial infarction and1.32 (95% CI 1.27–1.38) for stroke for each one-standard deviation 
difference of common carotid IMT. CIMT does predict future CHD events but is a slightly better 
predictor for cerebrovascular events. Folsom et al. [34] compared CAC with CIMT in a cohort of  
6698 subjects aged 45–84 years of age in four ethnic groups enrolled in MESA study and showed that 
the hazard of CVD increased 2.1 (95% CI 1.8–2.5) fold for log-transformed CAC vs. 1.3-fold (95% CI 
1.1–1.4) for maximum CIMT for each standard deviation increment of log-transformed CAC and 
maximum CIMT. For coronary heart disease, the hazard ratios per 1-SD increment increased 2.5-fold 
(95% CI 2.1–3.1) for CAC score and 1.2-fold (95% CI 1.0–1.4) for IMT. The study also showed CAC to 
be a superior predictor of incident CVD compared with CIMT (area under the curve 0.81 vs. 0.78), 
respectively. Terry et al. [35] compared the performance of CAC and CIMT for non-invasive detection 
of prevalent CAD (≥50% stenosis in one or more coronary arteries identified on coronary 
angiography). CAC performed better than CIMT in terms of prevalent CAD for each quartile increase 
in both measures (odds ratio: 8-fold vs. 1.7-fold, respectively). 
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CAC seems to be better than CIMT in patients with atherosclerosis CAD. However, among patients 
with coronary micro-vascular dysfunction, CIMT seem to perform better than CAC score.  
Danad et al. [36] evaluated 120 patients without documented evidence of CAD to compare CAC with 
CIMT for prediction of minimal coronary vascular resistance, a measure used to detect coronary 
micro-vascular disease [37]. Using bivariate and multivariable regression analysis using backward 
elimination revealed that only CIMT was a predictor of minimal coronary vascular resistance.  
Naqvi et al. [38] showed that CIMT based mean vascular age (61.6 ± 11.4 years) was significantly higher 
than coronary calcium age (58.3 ± 11.1 years) (p = 0.001); both of these were significantly higher than 
mean chronological age (p < 0.0001 and p < 0.04, respectively). CIMT was able to upgrade or 
downgrade FRS by >5% compared with CAC (42% of CIMT cases vs. 17% of CAC cases). 
Studies comparing CAC with CIMT in younger population groups, where the prevalence of CAC is 
very low, CIMT may perform better in those population groups. Davis et al. [39] performed a study in 
young population (33–42 years of age) evaluating the relationship of CAC with CIMT. The 
multivariate model showed low density cholesterol-C (p < 0.001), pack-year smoking (p < 0.005)  
and CAC (p < 0.05) were significant in men; and low density cholesterol-C (p < 0.001), systolic  
blood pressure (p < 0.01) and CAC (p < 0.05) were significant in women and were predictive of CIMT in 
this population. 
Lester et al. [40] performed a study on relatively younger population, aged 36–59 years of age, 
comparing CAC and CIMT to detect subclinical atherosclerosis. A large proportion of population had 
a CAC score of zero (75%). There was evidence of carotid atherosclerosis in 47% of the population 
with CAC score of zero, showing the role of CIMT in low risk, relatively younger population group 
with CAC score of zero. 
5. C-Reactive Protein and Coronary Artery Calcium 
AHA/ACC recommends measurement of C-reactive protein (CRP) in men 50 years of age or older 
or women 60 years of age or older with low-density lipoprotein cholesterol less than 130 mg/dL can be 
useful in selection of patients for statin therapy [41]. These recommendations are based on JUPITER 
trial [42] assessing the benefit of statin treatment in apparently healthy persons with hyperlipidemia 
(LDL-C < 130 mg/dL) but with elevated high-sensitivity CRP levels (hs-CRP ≥ 2 mg/dL). 
Measurement of hs-CRP has been shown as an independent prediction of future vascular events and 
improves global classification of risk, regardless of the LDL cholesterol level [43–49]. Arad et al. [22] 
performed a study evaluating 4903 apparently healthy middle-aged persons comparing CAC to 
standard coronary disease risk factors and CRP that were followed for a period of 4.3 years. CAC was 
shown to perform better than CRP and to highly correlate with future CAD events in this study.  
Park et al. [50] performed a study evaluating 1461 subjects without coronary heart disease comparing 
CAC and CRP in predicting cardiovascular events in non-diabetic individuals. The study showed that 
both CAC was predictive of non-fatal myocardial infarction or coronary death and any cardiovascular 
events (p < 0.005) whereas CRP was only predictive of cardiovascular events (p = 0.03). Risk group 
analysis that are defined by increasing tertiles for CAC (<3.7, 3.7–142.1, >142.1) and the 75th percentile 
for CRP (>4.05 mg/L) were associated with increasing risk with increasing CAC and CRP. Relative risks 
for the medium-calcium/low-CRP risk group to high-calcium/high-CRP risk group ranged from  
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1.8 to 6.1 for MI/coronary death (p = 0.003) and 2.8–7.5 for any cardiovascular event (p < 0.001).  
Lakoski et al. [51] examined the MESA participants to determine how many individuals risk can be 
reclassified with the use of CAC and CRP. The study showed that 30% of the intermediate-risk 
subjects by FRS had CRP concentration greater than 3 mg/L and 33% had CAC scores more than 100 AU. 
In gender specific analysis, 49% of intermediate-risk women and 27% of intermediate-risk men had 
CRP >3 mg/L, compared with 33% of intermediate-risk men and women had CAC >100 AU. When 
gender specific cut points for CRP and CAC were use, the same percentage of intermediate risk 
women and men had CRP above 75th percentile (28% and 27%, respectively) whereas more 
intermediate-risk women 40%, CAC > 50) than men (25%, CAC > 180) had a high CAC score. 
Blaha et al. [52] performed a study evaluating whether CAC score may further risk stratify  
a JUPITER-eligible population (LDL-C < 130 mg/dL and hs-CRP ≥ 2.0 mg/dL) in participants 
enrolled in MESA study. For CHD events, the five-year number needed to treat for CAC scores of 0, 
1–100 and >100 was 549, 94 and 24, respectively. In JUPITOR trial, the five-year number needed to 
prevent the occurrence of one primary end point was 25 [42]. The presence of CAC was associated 
with 4.3-fold increased CHD (95% CI 2.0–9.3) and 2.6-fold increased CVD (95% CI 1.5–4.5), while 
hs-CRP was not associated with either CHD or CVD after multivariable adjustment [52]. 
Möhlenkamp et al. [53] performed a study involving 3966 subjects without known CAD or acute 
inflammation, followed for 5.1 ± 0.3 years, to determine whether combined presence of CAC and  
hs-CRP improves discrimination and stratification of coronary events and all-cause mortality.  
For coronary events, net reclassification improvement (NRI) was 23.8% (p = 0.0007) for CAC and 
10.5% (p = 0.026) for hs-CRP. Addition of CAC to Framingham risk variables and hs-CRP improved 
discrimination of coronary risk but not vice versa. Among persons with CAC score of zero,  
hs-CRP >3 mg/L was associated with a significantly higher coronary event risk compared with hs-CRP 
<3.0 mg/L (p = 0.006). Reilly et al. [54] performed a study involving 914 participants from the Study 
of Inherited Risk of Coronary Atherosclerosis (SIRCA) who were free of clinical CAD and had  
a family history of premature CAD. The study showed that median CAC scores increased across 
ordinal CRP categories in women but not in men (Krushal-Wallis χ2 = 22.5, p < 0.001 in women,  
χ2 = 2.5, p < 0.29 in men, respectively). CRP levels were found to be significant predictors of CAC 
scores in women after adjusting for traditional risk factors, which was lost after adjustment for body 
mass index. There was no such association found between CRP and CAC in men. 
6. Coronary Artery Calcium and Other Imaging Parameters for Risk Prediction 
Various imaging markers that can be easily obtained from coronary artery calcium scan have  
been proposed for prediction of CHD and CVD events. Pericardial fat is present around the  
heart—encompassing the coronary arteries—has been shown to be a predictor of coronary events [55].  
Budoff et al. [56] showed that thoracic aortic wall calcification to be a significant predictor of incident 
coronary events in women, independent of CAC. Zeb et al. [57] showed liver fat measured by CT 
scans to be an independent predictor of incident coronary heart disease events. Yeboah et al. [58] 
performed a study to assess whether addition of computed tomography risk markers thoracic aorta 
calcium (TAC), aortic valve calcification (AVC), mitral annular calcification (MAC), pericardial 
adipose tissue volume (PAT), and liver attenuation (LA) to FRS + CAC provide improved 
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discrimination for incident CHD and incident CVD events. CAC, TAC, AVC and MAC were all 
significantly associated with incident CVD/CHD/mortality among intermediate risk subjects; CAC had 
the strongest association. The addition of CAC to the FRS provides superior discrimination especially 
in intermediate-risk individuals. Among participants with intermediate FRS risk, the addition of TAC, 
AVC, MAC, PAT, or LA to FRS + CAC resulted in a significant reduction in area of the curve for 
incident CHD (0.712 vs. 0.646, 0.655, 0.652, 0.648 and 0.569; all p < 0.01, respectively). The addition 
of CAC to FRS resulted in a superior discrimination for incident CHD in the intermediate-risk groups 
compared to when TAC, AVC, MAC, PAT and LA were added to FRS + CAC (0.024, 0.026, 0.019, 
0.012 and 0.012, respectively). These risk markers are unlikely to be useful for improving 
cardiovascular risk prediction. 
7. Conclusions 
CAC score has been shown as the strongest predictor of incident coronary events and is able to 
reclassify low-to-intermediate risk groups and certain subgroups, especially women and young adults 
most of which may be classified as low risk by FRS risk stratification. Most of the adult population 
will have CAC scores of zero (Table 1). The prevalence of CAC scores increases with increasing age. 
There is a number of different cutoffs that are used to denote increased CHD risk [20,59], however,  
the most commonly used cutoffs of increased CHD risk are CAC score 1–100, CAC 101–300 and  
CAC > 300 [20]. Studies have shown that subjects who undergo CAC scans tend to have better 
compliance rates with medications compared with other groups, and promote a healthy behavior in 
these patients (a picture equals a thousand words) [60,61]. CAC scans can be used to evaluate the 
efficacy of treatment regimens over time. The accelerated progression of CAC is associated with 
adverse cardiovascular events [62–65]. There are certain concerns associated with the use of CAC 
scores. Among them, the foremost concern associated with CAC use is radiation exposure. The recent 
advances in imaging techniques has lowered the radiation exposure associated with CAC scans and is 
comparable to mammograms in terms in radiation exposure (0.9 to 1.1 mSv) [66,67]. The scan can be 
easily performed in an outpatient setting without any prior preparation. Medicare is currently 
reimbursing the cost of CAC scans for selected population groups. Another issue that can arise with 
the use of CAC scans are incidental findings which can drive the cost upward due to further 
downstream testing as a result of these incidental findings. The prevalence of incidental findings can 
range from 4% to 8% [68–70]. There is a number of cost effectiveness analysis studies that are looking 
at the cost associated with the use of CAC scans. However, the information obtained with CAC can be 
very useful for earlier detection, institution of statins and prevention of adverse cardiovascular events. 
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